Eli Lilly and Company (BMV:LLY)

Market Cap	14.34T
Revenue (ttm)	1.09T
Net Income (ttm)	337.72B
Shares Out	n/a
EPS (ttm)	374.95
PE Ratio	42.46
Forward PE	29.07
Dividend	114.81 (0.72%)
Ex-Dividend Date	Aug 15, 2025

Volume	130
Average Volume	679
Open	15,800
Previous Close	15,617
Day's Range	15,800 - 16,048
52-Week Range	11,630 - 19,204
Beta	0.46
RSI	67.98
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD